{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:38:24Z","timestamp":1788021504991,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"none"},{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In this placebo-controlled trial, we aimed to evaluate the clinical results of using PDE-5 inhibitor, tadalafil 5\u00a0mg OD, for management of CP\/CPPS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>140 patients\u2009\u2264\u200945\u00a0years old with moderate\/severe CP\/CPPS associated with ED (IIEF-5\u2009&lt;\u200922) were randomly divided and received either tadalafil 5\u00a0mg OD (tadalafil-group) or placebo (control-group) for 6\u00a0weeks. Post-treatment CPSI scores were compared to baseline and to placebo. Clinically significant responders (\u2265\u200925% reduction from baseline score) were calculated. Tadalafil-induced changes in IIE-5 were evaluated in correlation to that of CPSI scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>By the 6th week, 59 and 56 patients were available in both groups respectively. Compared to baseline, tadalafil-group patients showed significant improvement in total, pain, urinary and Qol domains of CPSI (19.1\u2009\u00b1\u20095.26, 10.42\u2009\u00b1\u20093.55, 4.2\u2009\u00b1\u20091.72 and 4.47\u2009\u00b1\u20091.64 vs. 24.21\u2009\u00b1\u20095.05, 12.14\u2009\u00b1\u20093.57, 6.08\u2009\u00b1\u20091.53 and 6.22\u2009\u00b1\u20091.76), <jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.5<\/jats:italic>. When compared to placebo, all 6th week CPSI domains scores, except for pain, were significantly better in tadalafil-group (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.05<\/jats:italic>). Post-treatment pain score didn't significantly differ between both groups (10.42\u2009\u00b1\u20093.55, vs. 11.71\u2009\u00b1\u20093.9, <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Clinically significant responders were 30 patients (50.8%) in tadalafil-group vs. 3 patients (5.4%) in control. Tadalafil-induced changes in IIEF-5 score had weak but significant correlation to Qol domain (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u20090.28, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tadalafil 5\u00a0mg OD can significantly improve all CPSI domains as compared to baseline. Post-treatment CPSI scores, except for pain, were better than placebo. About 50.8% of patients can develop\u2009\u2265\u200925% reduction in their total CPSI scores after treatment. Apart from Qol domain, these changes are not significantly correlated to tadalafil-induced IIEF-5 scores changes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-022-04074-4","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T13:04:08Z","timestamp":1657285448000},"page":"2505-2511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tadalafil monotherapy in management of chronic prostatitis\/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial"],"prefix":"10.1007","volume":"40","author":[{"given":"Ahmed M.","family":"Tawfik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulmonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abo-Elenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir A.","family":"Elgamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed O.","family":"Aboufarha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"issue":"6","key":"4074_CR1","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.juro.2007.08.046","volume":"178","author":"R Bartoletti","year":"2007","unstructured":"Bartoletti R et al (2007) Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis\/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case\u2013control observational study. J Urol 178(6):2411\u20132415 (discussion 2415)","journal-title":"J Urol"},{"issue":"5","key":"4074_CR2","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.juro.2007.01.008","volume":"177","author":"M Marszalek","year":"2007","unstructured":"Marszalek M et al (2007) Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 177(5):1815\u20131819","journal-title":"J Urol"},{"issue":"6","key":"4074_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0090-4295(97)00235-5","volume":"49","author":"RO Roberts","year":"1997","unstructured":"Roberts RO et al (1997) A review of clinical and pathological prostatitis syndromes. Urology 49(6):809\u2013821","journal-title":"Urology"},{"issue":"5","key":"4074_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.urology.2005.05.007","volume":"66","author":"JC Nickel","year":"2005","unstructured":"Nickel JC et al (2005) Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: the Canadian PIE study. Urology 66(5):935\u2013940","journal-title":"Urology"},{"issue":"1","key":"4074_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jama.2010.1913","volume":"305","author":"T Anothaisintawee","year":"2011","unstructured":"Anothaisintawee T et al (2011) Management of chronic prostatitis\/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 305(1):78\u201386","journal-title":"JAMA"},{"issue":"4","key":"4074_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0090-4295(96)00234-8","volume":"48","author":"RB Alexander","year":"1996","unstructured":"Alexander RB, Trissel D (1996) Chronic prostatitis: results of an Internet survey. Urology 48(4):568\u2013574","journal-title":"Urology"},{"issue":"4","key":"4074_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bju.13101","volume":"116","author":"J Rees","year":"2015","unstructured":"Rees J et al (2015) Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome: a consensus guideline. BJU Int 116(4):509\u2013525","journal-title":"BJU Int"},{"issue":"5","key":"4074_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2164\/jandrol.110.012138","volume":"32","author":"ZY Hao","year":"2011","unstructured":"Hao ZY et al (2011) The prevalence of erectile dysfunction and its relation to chronic prostatitis in Chinese men. J Androl 32(5):496\u2013501","journal-title":"J Androl"},{"issue":"5","key":"4074_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1464-410X.2011.10807.x","volume":"110","author":"SD Chung","year":"2012","unstructured":"Chung SD, Keller JJ, Lin HC (2012) A case-control study on the association between chronic prostatitis\/chronic pelvic pain syndrome and erectile dysfunction. BJU Int 110(5):726\u2013730","journal-title":"BJU Int"},{"issue":"1","key":"4074_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2008.08.062","volume":"55","author":"TS Kohler","year":"2009","unstructured":"Kohler TS, McVary KT (2009) The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 55(1):38\u201348","journal-title":"Eur Urol"},{"issue":"4","key":"4074_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/1756287214531639","volume":"6","author":"K Hatzimouratidis","year":"2014","unstructured":"Hatzimouratidis K (2014) A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol 6(4):135\u2013147","journal-title":"Ther Adv Urol"},{"issue":"6","key":"4074_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.eururo.2006.09.014","volume":"50","author":"KT McVary","year":"2006","unstructured":"McVary KT (2006) Unexpected insights into pelvic function following phosphodiesterase manipulation\u2014what\u2019s next for urology? Eur Urol 50(6):1153\u20131156","journal-title":"Eur Urol"},{"issue":"15","key":"4074_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/pros.23690","volume":"78","author":"M Kurita","year":"2018","unstructured":"Kurita M et al (2018) Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain. Prostate 78(15):1157\u20131165","journal-title":"Prostate"},{"issue":"1","key":"4074_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12894-019-0525-x","volume":"19","author":"M Sugimoto","year":"2019","unstructured":"Sugimoto M et al (2019) A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. BMC Urol 19(1):99","journal-title":"BMC Urol"},{"issue":"6","key":"4074_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.urology.2008.11.041","volume":"73","author":"GT Kedia","year":"2009","unstructured":"Kedia GT et al (2009) Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology 73(6):1397\u20131401","journal-title":"Urology"},{"issue":"3","key":"4074_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1210\/en.2006-1079","volume":"148","author":"S Filippi","year":"2007","unstructured":"Filippi S et al (2007) Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148(3):1019\u20131029","journal-title":"Endocrinology"},{"issue":"3","key":"4074_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.eururo.2009.01.030","volume":"57","author":"T Roumeguere","year":"2010","unstructured":"Roumeguere T et al (2010) Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 57(3):522\u2013528","journal-title":"Eur Urol"},{"issue":"1","key":"4074_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mehy.2006.11.040","volume":"69","author":"SJ Grimsley","year":"2007","unstructured":"Grimsley SJ, Khan MH, Jones GE (2007) Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 69(1):25\u201326","journal-title":"Med Hypotheses"},{"issue":"3","key":"4074_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4081\/aiua.2013.3.109","volume":"85","author":"U Cantoro","year":"2013","unstructured":"Cantoro U et al (2013) Comparison of tamsulosin vs tamsulosin\/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis. Arch Ital Urol Androl 85(3):109\u2013112","journal-title":"Arch Ital Urol Androl"},{"issue":"7","key":"4074_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/nau.24454","volume":"39","author":"Y Matsukawa","year":"2020","unstructured":"Matsukawa Y et al (2020) Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis\/chronic pelvic pain syndrome: a randomized, prospective study. Neurourol Urodyn 39(7):1994\u20132002","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"4074_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.21037\/tau.2020.03.05","volume":"9","author":"K Pineault","year":"2020","unstructured":"Pineault K et al (2020) Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome. Transl Androl Urol 9(2):391\u2013397","journal-title":"Transl Androl Urol"},{"issue":"1","key":"4074_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/iju.14122","volume":"27","author":"I Hiramatsu","year":"2020","unstructured":"Hiramatsu I et al (2020) Tadalafil is sufficiently effective for severe chronic prostatitis\/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. Int J Urol 27(1):53\u201357","journal-title":"Int J Urol"},{"issue":"3","key":"4074_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000094814","volume":"77","author":"A El-Nashaar","year":"2006","unstructured":"El-Nashaar A et al (2006) Validity and reliability of the Arabic version of the National Institutes of Health Chronic Prostatitis Symptom Index. Urol Int 77(3):227\u2013231","journal-title":"Urol Int"},{"issue":"5","key":"4074_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/sj.ijir.3901248","volume":"16","author":"R Shamloul","year":"2004","unstructured":"Shamloul R, Ghanem H, Abou-zeid A (2004) Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res 16(5):452\u2013455","journal-title":"Int J Impot Res"},{"issue":"2","key":"4074_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11136-005-1317-1","volume":"15","author":"KJ Propert","year":"2006","unstructured":"Propert KJ et al (2006) Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 15(2):299\u2013305","journal-title":"Qual Life Res"},{"issue":"Suppl 1","key":"4074_CR26","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.ijantimicag.2007.07.028","volume":"31","author":"JC Nickel","year":"2008","unstructured":"Nickel JC (2008) Treatment of chronic prostatitis\/chronic pelvic pain syndrome. Int J Antimicrob Agents 31(Suppl 1):S112\u2013S116","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"4074_CR27","doi-asserted-by":"publisher","first-page":"c169","DOI":"10.1159\/000116887","volume":"108","author":"R Zeltner","year":"2008","unstructured":"Zeltner R et al (2008) A promoter polymorphism of the alpha 8 integrin gene and the progression of autosomal-dominant polycystic kidney disease. Nephron Clin Pract 108(3):c169\u2013c175","journal-title":"Nephron Clin Pract"},{"issue":"12","key":"4074_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1756287218808677","volume":"10","author":"A Benelli","year":"2018","unstructured":"Benelli A et al (2018) Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis\/chronic pelvic pain syndrome. Ther Adv Urol 10(12):377\u2013381","journal-title":"Ther Adv Urol"},{"issue":"1","key":"4074_CR29","first-page":"30","volume":"8","author":"JC Nickel","year":"2001","unstructured":"Nickel JC, Collins M, Litwin MS (2001) Development and use of a validated outcome measure for chronic prostatitis. JCOM-WAYNE PA 8(1):30\u201337","journal-title":"JCOM-WAYNE PA"},{"issue":"9","key":"4074_CR30","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/j.1743-6109.2008.00935.x","volume":"5","author":"H Porst","year":"2008","unstructured":"Porst H et al (2008) Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 5(9):2160\u20132169","journal-title":"J Sex Med"},{"key":"4074_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/560239","volume":"2015","author":"J Gao","year":"2015","unstructured":"Gao J et al (2015) Comparison of National Institutes of Health-Chronic Prostatitis Symptom Index with International Index of Erectile Function 5 in men with chronic prostatitis\/chronic pelvic pain syndrome: a large cross-sectional study in China. Biomed Res Int 2015:560239","journal-title":"Biomed Res Int"},{"issue":"10","key":"4074_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1525-1497.2001.01223.x","volume":"16","author":"M McNaughton Collins","year":"2001","unstructured":"McNaughton Collins M et al (2001) Quality of life is impaired in men with chronic prostatitis the chronic prostatitis collaborative research network. J Gen Intern Med 16(10):656\u2013662","journal-title":"J Gen Intern Med"},{"issue":"6","key":"4074_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/01.mou.0000186847.25259.28","volume":"15","author":"A Muller","year":"2005","unstructured":"Muller A, Mulhall JP (2005) Sexual dysfunction in the patient with prostatitis. Curr Opin Urol 15(6):404\u2013409","journal-title":"Curr Opin Urol"}],"updated-by":[{"DOI":"10.1007\/s00345-022-04128-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000}}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04074-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T16:08:32Z","timestamp":1664208512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["4074"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04074-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00345-022-04128-7","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00345-022-04128-7","URL":"https:\/\/doi.org\/10.1007\/s00345-022-04128-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research involved human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving humans and\/or animals"}},{"value":"An informed written consent was done by all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}